Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? - PubMed (original) (raw)

doi: 10.1038/mt.2011.288.

Richard A Morgan, Kenneth Cornetta, Carl H June, Gwendolyn Binder-Scholl, Mark E Dudley, Steven A Feldman, Steven A Rosenberg, Sheila A Shurtleff, Cliona M Rooney, Helen E Heslop, Gianpietro Dotti

Affiliations

• PMID: 22297819
• PMCID: PMC3277217
• DOI: 10.1038/mt.2011.288

Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?

Adham S Bear et al. Mol Ther. 2012 Feb.

No abstract available

PubMed Disclaimer

Similar articles

• Detection of replication competent retrovirus and lentivirus.
  Sastry L, Cornetta K. Sastry L, et al. Methods Mol Biol. 2009;506:243-63. doi: 10.1007/978-1-59745-409-4_17. Methods Mol Biol. 2009. PMID: 19110631
• Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.
  Cornetta K, Duffy L, Turtle CJ, Jensen M, Forman S, Binder-Scholl G, Fry T, Chew A, Maloney DG, June CH. Cornetta K, et al. Mol Ther. 2018 Jan 3;26(1):280-288. doi: 10.1016/j.ymthe.2017.09.008. Epub 2017 Sep 12. Mol Ther. 2018. PMID: 28970045 Free PMC article.
• A facile method to increase titers of miRNA-encoding retroviruses by inhibition of the RNaseIII enzyme Drosha.
  Brandl A, Wittmann J, Jäck HM. Brandl A, et al. Eur J Immunol. 2011 Feb;41(2):549-51. doi: 10.1002/eji.201040960. Epub 2010 Dec 29. Eur J Immunol. 2011. PMID: 21268023 No abstract available.
• Safety aspects of gene therapy.
  Cornetta K. Cornetta K. Br J Haematol. 1992 Apr;80(4):421-6. doi: 10.1111/j.1365-2141.1992.tb04552.x. Br J Haematol. 1992. PMID: 1581226 Review. No abstract available.
• Gene transfer in avian embryos using replication-competent retroviruses.
  Logan C, Francis-West P. Logan C, et al. Methods Mol Biol. 2008;461:363-76. doi: 10.1007/978-1-60327-483-8_26. Methods Mol Biol. 2008. PMID: 19030811 Review. No abstract available.

Cited by

• CAR T cells for hematological malignancies.
  Savoldo B, Grover N, Dotti G. Savoldo B, et al. J Clin Invest. 2024 Jan 16;134(2):e177160. doi: 10.1172/JCI177160. J Clin Invest. 2024. PMID: 38226627 Free PMC article. No abstract available.
• Long-term stability of clinical-grade lentiviral vectors for cell therapy.
  Jadlowsky JK, Leskowitz R, McKenna S, Karar J, Ma Y, Dai A, Plesa G, Chen F, Alexander K, Petrella J, Gong N, Hwang WT, Farrelly O, Barber-Rotenberg J, Christensen S, Gonzalez VE, Chew A, Fraietta JA, June CH. Jadlowsky JK, et al. Mol Ther Methods Clin Dev. 2024 Jan 10;32(1):101186. doi: 10.1016/j.omtm.2024.101186. eCollection 2024 Mar 14. Mol Ther Methods Clin Dev. 2024. PMID: 38282894 Free PMC article.
• Advances in manufacturing chimeric antigen receptor immune cell therapies.
  Ramamurthy A, Tommasi A, Saha K. Ramamurthy A, et al. Semin Immunopathol. 2024 Aug 16;46(5):12. doi: 10.1007/s00281-024-01019-4. Semin Immunopathol. 2024. PMID: 39150566 Review.
• Reversal of tumor immune inhibition using a chimeric cytokine receptor.
  Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK, Vera JF. Leen AM, et al. Mol Ther. 2014 Jun;22(6):1211-1220. doi: 10.1038/mt.2014.47. Epub 2014 Mar 20. Mol Ther. 2014. PMID: 24732709 Free PMC article.
• Lipid- and Polymer-Based Nanoparticle Systems for the Delivery of CRISPR/Cas9.
  Ashok B, Peppas NA, Wechsler ME. Ashok B, et al. J Drug Deliv Sci Technol. 2021 Oct;65:102728. doi: 10.1016/j.jddst.2021.102728. Epub 2021 Jul 11. J Drug Deliv Sci Technol. 2021. PMID: 34335878 Free PMC article.

References

1. 1. Rosenberg SA., and, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233–240. - PMC - PubMed
2. 1. Brenner MK., and, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010;22:251–257. - PMC - PubMed
3. 1. Vera JF, Brenner MK., and, Dotti G. Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther. 2009;9:396–408. - PMC - PubMed
4. 1. Hacein-Bey-Abina S, von Kalle KC, Schmidt M, Le Deist F, Wulffraat N, McIntyre E.et al. (2003A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency N Engl J Med 348255–256. - PubMed
5. 1. Donahue RE, Kessler SW, Bodine D, McDonagh K, Dunbar C, Goodman S.et al. (1992Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer J Exp Med 1761125–1135. - PMC - PubMed

Publication types

MeSH terms

Grants and funding

• P01 CA094237-10/CA/NCI NIH HHS/United States
• T32 HL092332/HL/NHLBI NIH HHS/United States
• P50 CA126752/CA/NCI NIH HHS/United States
• P01CA094237/CA/NCI NIH HHS/United States
• 5U54HL081007/HL/NHLBI NIH HHS/United States
• U54 HL081007-05/HL/NHLBI NIH HHS/United States
• P40 RR024928/RR/NCRR NIH HHS/United States
• P50 CA126752-05/CA/NCI NIH HHS/United States
• P40 HL116242/HL/NHLBI NIH HHS/United States
• 3P50CA126752/CA/NCI NIH HHS/United States
• U54 HL081007/HL/NHLBI NIH HHS/United States
• P40 RR024928-03/RR/NCRR NIH HHS/United States
• P01 CA094237/CA/NCI NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information